Clinical-stage biotech treasuries are quietly modernizing. The old playbook — laddered T-bills and a sleepy commercial bank — is giving way to multi-currency wallets and stablecoin settlement for CRO payments.
The driver isn't yield. It's the operational reality of running trials across six countries with different banking rails.
